# Preclinical assessment of oral TLR7 agonist SA-5 in a nonhuman primate model

## TL;DR

SA-5, a new oral TLR7 agonist, shows safe immune stimulation in both young and aged macaques, suggesting potential as a safer immunotherapy.

## Contribution

SA-5 is a novel, orally available, liver-targeted TLR7 agonist with reduced systemic toxicity compared to existing agents.

## Key findings

- SA-5 induces dose-dependent type I IFN with limited systemic inflammation.
- SA-5 shows comparable immunostimulatory activity to GS-9620 but with fewer adverse effects.
- Efficacy is maintained in aged macaques with only modestly increased safety responses.

## Abstract

TLR7 agonists are promising immunostimulatory agents for the treatment of chronic infections and cancer. However, their systemic toxicity remains a challenge. In this study, SA-5, a potentially novel liver-targeted, orally available TLR7 agonist, was evaluated for pharmacokinetics, safety, and efficacy in young and aged macaques across 1–10 mg/kg repeated doses. Safety was evaluated through hematologic, biochemical, and flow cytometric profiling, while efficacy was assessed via IFN-α production, gene expression of IFN-stimulated genes, and plasmacytoid dendritic cell activation. A principal component analysis–based (PCA-based) composite scoring system was used to integrate multimodal parameters. SA-5 induced dose-dependent type I IFN with limited systemic inflammation, with 3 mg/kg showing optimal balance. SA-5 had comparable immunostimulatory activity to GS-9620 but with reduced adverse biomarker shifts. In aged macaques, efficacy was maintained with modestly increased safety responses. These findings support SA-5 as a safer next-generation TLR7 agonist effective across age groups, highlighting integrated biomarker profiling in preclinical immunomodulatory drug development.

SA-5, a novel oral TLR7 agonist, safely stimulates immune responses in young and aged macaques, supporting its potential as a next-generation immunotherapy.